Biosensors International Group has received CE Mark approval for its BioMatrix drug-eluting stent (DES) system, enabling commercialization of the product in the European Union and the countries in Asia and Latin America that recognize the CE Mark.

The Singapore-based company said its BioMatrix DES system consists of a DES that incorporates a biodegradable polymer and its proprietary drug, Biolimus A9, which inhibits restenosis.